Cargando…
Evaluating targeted COVID-19 vaccination strategies with agent-based modeling
We evaluate approaches to vaccine distribution using an agent-based model of human activity and COVID-19 transmission calibrated to detailed trends in cases, hospitalizations, deaths, seroprevalence, and vaccine breakthrough infections in Florida, USA. We compare the incremental effectiveness for fo...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029084/ https://www.ncbi.nlm.nih.gov/pubmed/36945423 http://dx.doi.org/10.1101/2023.03.09.23285319 |
_version_ | 1784910074057064448 |
---|---|
author | Hladish, Thomas J. Pillai, Alexander N. Pearson, Carl A. B. Toh, Kok Ben Tamayo, Andrea Stoltzfus, Arlin Longini, Ira M. |
author_facet | Hladish, Thomas J. Pillai, Alexander N. Pearson, Carl A. B. Toh, Kok Ben Tamayo, Andrea Stoltzfus, Arlin Longini, Ira M. |
author_sort | Hladish, Thomas J. |
collection | PubMed |
description | We evaluate approaches to vaccine distribution using an agent-based model of human activity and COVID-19 transmission calibrated to detailed trends in cases, hospitalizations, deaths, seroprevalence, and vaccine breakthrough infections in Florida, USA. We compare the incremental effectiveness for four different distribution strategies at four different levels of vaccine availability, reflecting different income settings’ historical COVID-19 vaccine distribution. Our analysis indicates that the best strategy to reduce severe outcomes is to actively target high disease-risk individuals. This was true in every scenario, although the advantage was greatest for the middle-income-country availability assumptions, and relatively modest compared to a simple mass vaccination approach for rapid, high levels of vaccine availability. Ring vaccination, while generally the most effective strategy for reducing infections, ultimately proved least effective at preventing deaths. We also consider using age group as a practical, surrogate measure for actual disease-risk targeting; this approach still outperforms both simple mass distribution and ring vaccination. We also find that the magnitude of strategy effectiveness depends on when assessment occurs (e.g., after delta vs. after omicron variants). However, these differences in absolute benefit for the strategies do not change the ranking of their performance at preventing severe outcomes across vaccine availability assumptions. |
format | Online Article Text |
id | pubmed-10029084 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-100290842023-03-22 Evaluating targeted COVID-19 vaccination strategies with agent-based modeling Hladish, Thomas J. Pillai, Alexander N. Pearson, Carl A. B. Toh, Kok Ben Tamayo, Andrea Stoltzfus, Arlin Longini, Ira M. medRxiv Article We evaluate approaches to vaccine distribution using an agent-based model of human activity and COVID-19 transmission calibrated to detailed trends in cases, hospitalizations, deaths, seroprevalence, and vaccine breakthrough infections in Florida, USA. We compare the incremental effectiveness for four different distribution strategies at four different levels of vaccine availability, reflecting different income settings’ historical COVID-19 vaccine distribution. Our analysis indicates that the best strategy to reduce severe outcomes is to actively target high disease-risk individuals. This was true in every scenario, although the advantage was greatest for the middle-income-country availability assumptions, and relatively modest compared to a simple mass vaccination approach for rapid, high levels of vaccine availability. Ring vaccination, while generally the most effective strategy for reducing infections, ultimately proved least effective at preventing deaths. We also consider using age group as a practical, surrogate measure for actual disease-risk targeting; this approach still outperforms both simple mass distribution and ring vaccination. We also find that the magnitude of strategy effectiveness depends on when assessment occurs (e.g., after delta vs. after omicron variants). However, these differences in absolute benefit for the strategies do not change the ranking of their performance at preventing severe outcomes across vaccine availability assumptions. Cold Spring Harbor Laboratory 2023-03-10 /pmc/articles/PMC10029084/ /pubmed/36945423 http://dx.doi.org/10.1101/2023.03.09.23285319 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator. |
spellingShingle | Article Hladish, Thomas J. Pillai, Alexander N. Pearson, Carl A. B. Toh, Kok Ben Tamayo, Andrea Stoltzfus, Arlin Longini, Ira M. Evaluating targeted COVID-19 vaccination strategies with agent-based modeling |
title | Evaluating targeted COVID-19 vaccination strategies with agent-based modeling |
title_full | Evaluating targeted COVID-19 vaccination strategies with agent-based modeling |
title_fullStr | Evaluating targeted COVID-19 vaccination strategies with agent-based modeling |
title_full_unstemmed | Evaluating targeted COVID-19 vaccination strategies with agent-based modeling |
title_short | Evaluating targeted COVID-19 vaccination strategies with agent-based modeling |
title_sort | evaluating targeted covid-19 vaccination strategies with agent-based modeling |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029084/ https://www.ncbi.nlm.nih.gov/pubmed/36945423 http://dx.doi.org/10.1101/2023.03.09.23285319 |
work_keys_str_mv | AT hladishthomasj evaluatingtargetedcovid19vaccinationstrategieswithagentbasedmodeling AT pillaialexandern evaluatingtargetedcovid19vaccinationstrategieswithagentbasedmodeling AT pearsoncarlab evaluatingtargetedcovid19vaccinationstrategieswithagentbasedmodeling AT tohkokben evaluatingtargetedcovid19vaccinationstrategieswithagentbasedmodeling AT tamayoandrea evaluatingtargetedcovid19vaccinationstrategieswithagentbasedmodeling AT stoltzfusarlin evaluatingtargetedcovid19vaccinationstrategieswithagentbasedmodeling AT longiniiram evaluatingtargetedcovid19vaccinationstrategieswithagentbasedmodeling |